StreetInsider.com News Articles

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Thu, 20 Aug 2026 09:44:00 -0400

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw

Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS, MD, FACP, special presentation entitled: "Vascular Cognitive Impairment and Vascular Dementia: Recognizing the Vascular Cause and Exploring the Clinical-Trial Application of VesCell™". The presentation will begin at 12:00 EST and is available through https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw

Dementia debilitates

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA

Thu, 20 Aug 2026 09:44:00 -0400

Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™ (ACP-01) today at 12:00 EST, at https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce > 130 participants have enrolled to hear Dr. William R. Shankle, MS, MD, FACP, special presentation entitled: "Vascular Cognitive Impairment and Vascular Dementia: Recognizing the Vascular Cause and Exploring the Clinical-Trial Application of VesCell™". The presentation will begin at 12:00 EST and is available through https://us06web.zoom.us/webinar/register/WN_nJ8ViLkRSeiU_NXMYJ-jbw
Dementia debilitates

Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial

Wed, 12 Aug 2026 08:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial.
The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular health associated with health-span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function, and immune system improvement as measured by decreased inflammation.
About Prof. Dr. Ernst von Schwarz
Dr. von

Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial

Wed, 12 Aug 2026 08:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial.
The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular health associated with health-span (healthy active aging), improvements in muscle function as measured by the six minute walk test, cognitive function, and immune system improvement as measured by decreased inflammation.
About Prof. Dr. Ernst von Schwarz
Dr. von

Hemostemix closes second tranche, raises CDN$322,250

Thu, 30 Jul 2026 17:59:11 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) closed the second tranche of a non-brokered private placement, raising CDN$322,250 through the issuance of 6,445,000 units priced at CDN$0.05 per unit, according to a company statement.

Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at CDN$0.12 per share for 24 months from the closing date. The company may accelerate warrant expiry to 30 days' notice if the volume-weighted average trading price on the TSX Venture Exchange reaches or exceeds CDN$0.15 per share for 10 consecutive

Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

Thu, 30 Jul 2026 17:57:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05 per
Unit.Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles

Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

Thu, 30 Jul 2026 17:57:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05 per
Unit.Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles

Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results

Tue, 28 Jul 2026 12:14:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted.
The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of cardiovascular diseases, toward improving healthspan—the number of years people enjoy health, pain free, remaining active, strong, independent, mentally sharp and cognitively competent.
The commercial Phase I clinical trial is designed to study and leverage how VesCell™ improves

Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results

Tue, 28 Jul 2026 12:14:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted.
The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of cardiovascular diseases, toward improving healthspan—the number of years people enjoy health, pain free, remaining active, strong, independent, mentally sharp and cognitively competent.
The commercial Phase I clinical trial is designed to study and leverage how VesCell™ improves

Hemostemix Grants Stock Options

Wed, 22 Jul 2026 16:50:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.
Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and 1,745,000 Options vest as to 50% on July 22, 2026, and 50% on July 22, 2027. After this Option issuance, Hemostemix has 20,496,694 Options issued and

Hemostemix Grants Stock Options

Wed, 22 Jul 2026 16:50:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants.
Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant, and 1,745,000 Options vest as to 50% on July 22, 2026, and 50% on July 22, 2027. After this Option issuance, Hemostemix has 20,496,694 Options issued and

Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain

Wed, 08 Jul 2026 10:08:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Published in Circulation, Tresukosol et al evaluated VesCell™ in a phase I clinical trial of 24 patients suffering from chronic stable angina. The results showed statistically significant improvements in several important measures of

Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain

Wed, 08 Jul 2026 10:08:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Published in Circulation, Tresukosol et al evaluated VesCell™ in a phase I clinical trial of 24 patients suffering from chronic stable angina. The results showed statistically significant improvements in several important measures of

Hemostemix raises CDN$360,000 in first tranche of private placement

Fri, 26 Jun 2026 08:49:17 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) has closed the first tranche of a non-brokered private placement, raising CDN$360,000 through the issuance of 7,200,000 units at CDN$0.05 per unit, according to a company statement.

Each unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at CDN$0.12 for 24 months from the closing date. The company may accelerate warrant expiry to 30 days' notice if the volume-weighted average trading price on the TSX Venture Exchange reaches or exceeds CDN$0.15 for any 10 consecutive trading days after

Hemostemix Closes $360,000 First Tranche of Private Placement

Fri, 26 Jun 2026 08:47:00 -0400

Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at a price of CDN$0.05 per Unit.
Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each

Hemostemix Closes $360,000 First Tranche of Private Placement

Fri, 26 Jun 2026 08:47:00 -0400

Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at a price of CDN$0.05 per Unit.
Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each

Hemostemix closes $1M private placement, restates Q3 financials

Wed, 17 Jun 2026 17:24:18 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) announced it is closing up to $1,000,000 in a non-brokered private placement, selling units at $0.05 each. Each unit consists of one common share and one half common share purchase warrant, with each whole warrant entitling the holder to purchase one common share at $0.12 for 24 months from closing.

The warrants include an accelerated expiry provision: if the weighted average closing price of the common shares on the TSX Venture Exchange equals or exceeds $0.15 for 10 consecutive trading days after four months and one day from closing, the company may accelerate the warrant

Hemostemix' $1,000,000 Private Placement and Update

Wed, 17 Jun 2026 17:22:00 -0400

Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $0.12 per Common Share for a period of 24 months from the closing of the

Hemostemix' $1,000,000 Private Placement and Update

Wed, 17 Jun 2026 17:22:00 -0400

Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $0.12 per Common Share for a period of 24 months from the closing of the

Hemostemix Leadership Attending Abundance360 Summit

Mon, 09 Mar 2026 11:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week.
Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential technologies expected to reshape human health.
At this event, Hemostemix Inc. is describing ACP-01 (VesCell), as a regenerative treatment designed to increase health span via microvascular circulation, as it drives the growth of new

Hemostemix Leadership Attending Abundance360 Summit

Mon, 09 Mar 2026 11:23:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week.
Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential technologies expected to reshape human health.
At this event, Hemostemix Inc. is describing ACP-01 (VesCell), as a regenerative treatment designed to increase health span via microvascular circulation, as it drives the growth of new

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Tue, 03 Feb 2026 08:55:00 -0400

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant.
"Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?' Without exception, the answer has been an enthusiastic 'Yes'. When Dr. Hsiang answered that question, he added something I have

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Tue, 03 Feb 2026 08:55:00 -0400

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant.
"Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?' Without exception, the answer has been an enthusiastic 'Yes'. When Dr. Hsiang answered that question, he added something I have

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Fri, 16 Jan 2026 12:26:00 -0400

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA).
Hemostemix' team included Thomas Smeenk, CEO; Dr. Ina Sarel, Chief Scientific Officer; Dr. Fraser Henderson, Chief Medical Officer, Professor of Neurosurgery and a practicing neurosurgeon; Dr. Ernst von Schwarz, a triple board-certified transplant

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Fri, 16 Jan 2026 12:26:00 -0400

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA).
Hemostemix' team included Thomas Smeenk, CEO; Dr. Ina Sarel, Chief Scientific Officer; Dr. Fraser Henderson, Chief Medical Officer, Professor of Neurosurgery and a practicing neurosurgeon; Dr. Ernst von Schwarz, a triple board-certified transplant